| For: | Said I, Ahad H, Said A. Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. World J Gastrointest Oncol 2022; 14(5): 947-958 [PMID: 35646285 DOI: 10.4251/wjgo.v14.i5.947] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v14/i5/947.htm |
| Number | Citing Articles |
| 1 |
Connor Campbell, Mrunmayee R. Kandalgaonkar, Rachel M. Golonka, Beng San Yeoh, Matam Vijay-Kumar, Piu Saha. Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy. Biomedicines 2023; 11(2) doi: 10.3390/biomedicines11020294
|
| 2 |
Jie-ping Wang, Meng-yu Zhang, Ming Luo, Shu Qin, Xian-ming Xia. Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-23539-5
|
| 3 |
Xiumei Guo, Ying Zhao, Yanbing Pan, Jinrun Huang, Zhensan Wang, Pengkun Li, Weijuan Yuan, Yilin He, Jingshuo Qiu, Jinkang Dong, Zhihui Yan, Xinyue Zhang, Lintao Wang, Chengjie Guo, Yang An, Shuangyu Lv. Deciphering influence and therapeutic significance of gut microbiota and its metabolites on metabolic diseases and inflammatory bowel disease. Clinical Nutrition ESPEN 2025; 70 doi: 10.1016/j.clnesp.2025.10.021
|
| 4 |
Stergios A. Polyzos, Lampros Chrysavgis, Ilias D. Vachliotis, Evangelos Chartampilas, Evangelos Cholongitas. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy. Seminars in Cancer Biology 2023; 93 doi: 10.1016/j.semcancer.2023.04.010
|
| 5 |
Qinge Ma, Kejia Liu, Chenyu Chang, Lei Wang, Zhangyang Shen, Jiaxin Li, Mozili Adu, Qingyuan Lin, Huilian Huang, Xutao Wu, Rongrui Wei. Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review). International Journal of Molecular Medicine 2025; 56(6) doi: 10.3892/ijmm.2025.5668
|
| 6 |
Gursimran Singh, Shazia Ansari, Satyam Yadav, Khadga Raj Aran. Gut microbiota's role in NAFLD- and HBV/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications. Microbial Pathogenesis 2026; 211 doi: 10.1016/j.micpath.2025.108273
|
| 7 |
Bin Li, Xiaochen Chi, Ying Huang, Weitong Wang, Zhuo Liu. Bifidobacterium longum-Derived Extracellular Vesicles Prevent Hepatocellular Carcinoma by Modulating the TGF-β1/Smad Signaling in Mice. Frontiers in Bioscience-Landmark 2024; 29(7) doi: 10.31083/j.fbl2907241
|
| 8 |
Fahad Alfhaid. A Review of the Gut Microbiome and Its Role in Non-alcoholic Fatty Liver Disease. Advances in Human Biology 2026; 16(1) doi: 10.4103/aihb.aihb_19_25
|
| 9 |
Lisi Liu, Xun Duan, Baozhao Ju. Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies. Frontiers in Oncology 2026; 15 doi: 10.3389/fonc.2025.1744299
|
| 10 |
Yu Geng, Lanqing Liu, Yongping Sun, Lijuan Guo, Yuanjing Wu, Zhen Jia. Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1705723
|
| 11 |
Himanshi Goyal, Kaneez Fatima, Jyotdeep Kaur. Understanding crosstalk between the gut and liver microbiome: pathogenesis to therapeutic approaches in liver cancer. Cancer Cell International 2025; 25(1) doi: 10.1186/s12935-025-03840-9
|
| 12 |
Sara Tharwat Abdullah, Snur Rasool Abdullah, Bashdar Mahmud Hussen, Yousif Mohammed Younis, Mohammed Fatih Rasul, Mohammad Taheri. Role of circular RNAs and gut microbiome in gastrointestinal cancers and therapeutic targets. Non-coding RNA Research 2024; 9(1) doi: 10.1016/j.ncrna.2023.12.002
|
| 13 |
Maryam K. Ibrahim, Tracey G. Simon, Mary E. Rinella. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2023; 27(2) doi: 10.1016/j.cld.2023.01.004
|
| 14 |
Mohamed Salaheldin, Heba Aly, Louis Lau, Shimaa Afify, Mohamed El-Kassas. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis. Diagnostics 2023; 13(16) doi: 10.3390/diagnostics13162631
|
| 15 |
Shivendra Dixit, Antonia Welker, Diego Ortiz, Marina Athanasouli, Christoph K. Stein-Thoeringer. Microbiome dysbiosis and its modulation in cancer development, prevention and therapy. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1852716
|
| 16 |
Lei Chen, Meijun Liu, Xiaoli Chen, Aiping Lyu, Kenneth Cheung, Yongai Xiong. Interactions between traditional chinese medicine and gut microbiota in chronic diseases. Pharmacological Research - Modern Chinese Medicine 2025; 16 doi: 10.1016/j.prmcm.2025.100659
|
| 17 |
Aswathi Ramesh, Rajasekaran Subbarayan, Dhasarathdev Srinivasan, Ranjith Balakrishnan, Rupendra Shrestha, Ankush Chauhan. Gut microbiota-mediated oncogenesis in hepatocellular carcinoma: a new avenue for therapeutic intervention. International Journal of Surgery 2026; 112(2) doi: 10.1097/JS9.0000000000003851
|
| 18 |
Rui Xiao, Yang Cao, Linlin Wang, Peijun Tian, Qixiao Zhai, Jianxin Zhao, Gang Wang, Yu Zhu. The role of probiotics in the treatment of non-alcoholic fatty liver disease (NAFLD): New insights based on meta-analysis and subgroup analysis. Food Bioscience 2024; 62 doi: 10.1016/j.fbio.2024.105454
|
| 19 |
Renuka Sri Sai Peddireddi, Sai Kiran Kuchana, Rohith Kode, Saketh Khammammettu, Aishwarya Koppanatham, Supriya Mattigiri, Harshavardhan Gobburi, Suresh K. Alahari. Role of Gut Microbiome in Oncogenesis and Oncotherapies. Cancers 2025; 18(1) doi: 10.3390/cancers18010099
|
| 20 |
阳阳 张. Discussion on the Influence of Intestinal Flora Disturbance on Diabetic Nephropathy and the Treatment of Traditional Chinese Medicine Based on the Theory of “Entero-Renal Axis”. Traditional Chinese Medicine 2024; 13(09) doi: 10.12677/tcm.2024.139361
|
| 21 |
Ming Ren Toh, Evelyn Yi Ting Wong, Sunny Hei Wong, Alvin Wei Tian Ng, Lit-Hsin Loo, Pierce Kah-Hoe Chow, Joanne Ngeow. Global Epidemiology and Genetics of Hepatocellular Carcinoma. Gastroenterology 2023; 164(5) doi: 10.1053/j.gastro.2023.01.033
|
| 22 |
Tamiris Ingrid Petito‐da‐Silva, Felipe Missiba Villardi, Aline Penna‐de‐Carvalho, Carlos Alberto Mandarim‐de‐Lacerda, Vanessa Souza‐Mello, Sandra Barbosa‐da‐Silva. An Intestinal FXR Agonist Mitigates Dysbiosis, Intestinal Tight Junctions, and Inflammation in High‐Fat Diet‐Fed Mice. Molecular Nutrition & Food Research 2024; 68(4) doi: 10.1002/mnfr.202300148
|
| 23 |
Maria Pallozzi, Valeria De Gaetano, Natalia Di Tommaso, Lucia Cerrito, Francesco Santopaolo, Leonardo Stella, Antonio Gasbarrini, Francesca Romana Ponziani. Role of Gut Microbial Metabolites in the Pathogenesis of Primary Liver Cancers. Nutrients 2024; 16(14) doi: 10.3390/nu16142372
|
| 24 |
Ernesto Saenz, Nathally Espinosa Montagut, Baohong Wang, Christoph Stein-Thöringer, Kaicen Wang, Honglei Weng, Matthias Ebert, Kai Markus Schneider, Lanjuan Li, Andreas Teufel. Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges. Engineering 2024; 40 doi: 10.1016/j.eng.2024.03.019
|
| 25 |
Rong Feng, Liang Chen, Ming Yang. Aluminum-induced oxidative stress promotes changes in the structure of the gut microbiota and liver deficiency. Heliyon 2024; 10(16) doi: 10.1016/j.heliyon.2024.e36165
|